The American Society of Clinical Oncology (ASCO), Society for Neuro-Oncology (SNO) and American Society for Radiation Oncology (ASTRO) recommend for patients with asymptomatic NSCLC brain metastases that have a mutation in EGFR, ALK or ROS1 genes, primarily treatment with targeted agents.36 The gene discussed is ALK; the disease is non-small cell lung carcinoma.